Japan's MHLW action plan urges generic drugmakers to improve practices

29 October 2007

The Japanese Ministry of Health, Labor and Welfare has recently compiled an action plan to promote the use of generic medicines in accordance with the goal of increasing their share of the market to 30% (twice that of now on a volume basis) by 2012. This objective was set out in the Japanese prescription drug market proposal in the Basic Policy of Economic and Fiscal Reform for 2007 of the government presented in June.

The new action plan sets out concrete achievements and numerical goals that the government and generic drug manufacturers should reach by the end of fiscal 2007 through 2012, by categorizing the main issues such as stable supply, ensuring quality, providing drug information, improving the infrastructure for promoting the use of copy products and the matters related to medical fees and prescription format.

With regard to a stable supply, the plan calls on generic drug manufacturers to ensure a system of shipping all products the day after an order is placed during the fiscal year 2007, and 75% of products the next day, unless a wholesaler has no stocks, within fiscal 2008.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight